Related Experiment Videos
Biochemotherapy for advanced melanoma
Ulrich Keilholz1, Martin E Gore
1Department of Medicine III (Hematology, Oncology, and Transfusion Medicine), University Hospital Benjamin Franklin, Free University of Berlin, Berlin, Germany.
Abstract:
The outcome of chemotherapy for patients with stage IV melanoma is unsatisfactory, since durable responses are rarely achieved. More experimental treatments, such as vaccine approaches, antibody treatments, and gene therapy are being developed and are of high scientific interest; however, their efficacy in advanced melanoma patients has so far been very limited. Based on the observation of a small proportion of long-term responses, the use of biotherapy or biochemotherapy is currently preferred in many institutions as first-line treatment in stage IV melanoma. Various interleukin-2 (IL-2) dosing schedules and combinations with interferon alpha (IFN-alpha) have been tested in patients with advanced melanoma during the past decade. The response rates reported with IL-2 as a single agent or in combination with IFN-alpha varies from 10% to 41%, with a small, but remarkable proportion of durable responses. Subsequently, biochemotherapy regimens combining IL-2, IFN-alpha, and chemotherapy have been evaluated in phase II trials, which have suggested improved response rates. Recent randomized trials have investigated the role of biochemotherapy as compared to biotherapy alone or as compared to chemotherapy for the treatment of advanced melanoma. So far, none of the approaches has been proven to confer a survival benefit and thus the uniform desire is to include as many patients as possible in controlled clinical trials.
Insights
Biochemotherapy, combining interleukin-2 (IL-2) and interferon alpha (IFN-alpha) with chemotherapy, shows promise for advanced melanoma. While durable responses are rare with chemotherapy alone, these novel treatments offer improved response rates in clinical trials.
Area of Science:
- Oncology
- Immunotherapy
- Melanoma Research
Background:
- Chemotherapy for stage IV melanoma yields unsatisfactory outcomes with limited durable responses.
- Experimental treatments like vaccines and gene therapy have shown limited efficacy in advanced melanoma patients.
Purpose of the Study:
- To evaluate the efficacy of biotherapy and biochemotherapy as first-line treatments for stage IV melanoma.
- To compare biochemotherapy regimens with biotherapy alone and chemotherapy in randomized trials.
Main Methods:
- Review of various interleukin-2 (IL-2) dosing schedules and combinations with interferon alpha (IFN-alpha).
- Evaluation of biochemotherapy regimens combining IL-2, IFN-alpha, and chemotherapy in phase II trials.
- Analysis of recent randomized trials comparing biochemotherapy to biotherapy or chemotherapy.
Main Results:
- IL-2, alone or with IFN-alpha, shows response rates from 10% to 41%, including durable responses.
- Biochemotherapy regimens suggest improved response rates compared to biotherapy alone.
- No current approach has definitively proven a survival benefit in advanced melanoma.
Conclusions:
- Biochemotherapy is a preferred first-line treatment for stage IV melanoma due to observed response rates.
- Further research and inclusion in controlled clinical trials are necessary to establish survival benefits.
- Developing effective treatments for advanced melanoma remains a critical area of research.